TACRINE HYDROCHLORIDE MONOHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H14N2.ClH.H2O
Molecular Weight	252.74
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TACRINE HYDROCHLORIDE MONOHYDRATE

Structure Search

SMILES

O.Cl.NC1=C2CCCCC2=NC3=C1C=CC=C3

InChI

InChIKey=PXGRMZYJAOQPNZ-UHFFFAOYSA-N

InChI=1S/C13H14N2.ClH.H2O/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;;/h1,3,5,7H,2,4,6,8H2,(H2,14,15);1H;1H2

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H14N2
Molecular Weight	198.2637
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00382
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Acetylcholinesterase 207 Target ID: CHEMBL220 Sources: http://www.drugbank.ca/drugs/DB00382	Inhibitor 8228	500.0 nM [IC50]
Butyrylcholinesterase 46 Target ID: CHEMBL1914 Sources: http://www.drugbank.ca/drugs/DB00382	Inhibitor 8228	23.0 nM [IC50]
Histamine N-methyltransferase 10 Target ID: CHEMBL2190 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15834447	Inhibitor 8228	0.46 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 268 Sources: https://www.drugs.com/pro/cognex.html	Primary		Approved 8360	Cognex Approved Use Cognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Launch Date 7.474464E11

C_max

Value	Dose	Co-administered	Analyte	Population
15.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
91.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (21 patient) Vomiting (21 patient) Anorexia (21 patient) Dyspepsia (21 patient) Diarrhea (21 patient) Abdominal pain (21 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	Disc. AE: Transaminases increased, Atrial fibrillation... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Atrial fibrillation (1 patient) Dyspnea (1 patient) Chest pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	Disc. AE: Transaminases increased, Nausea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Nausea (1 patient) Vomiting (1 patient) Pallor (1 patient) Vasodilatation (1 patient) Sweating increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1032 OCT1 322 OCT3 79 OCTN2 50 P-gp 1527

Drug as victim

Target	Modality	Activity
P-gp 1527	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	inconclusive
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16128907/;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014350/	yes
OCT1 322	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes
OCT3 79	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes
OCTN2 50	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://academic.oup.com/toxsci/article-pdf/136/2/581/16686164/kft205.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45980	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45980
ChemicalBook	CB7699634	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7699634
MolPort	MolPort-000-881-472	https://www.molport.com/shop/molecule-link/MolPort-000-881-472
ZINC	ZINC000019014866	http://zinc15.docking.org/substances/ZINC000019014866
eMolecules	872890	https://www.emolecules.com/cgi-bin/more?vid=872890

PubMed

Title	Date	PubMed
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.	1992 Mar 20	1552502
Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat.	1993 Mar	8490946
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.	1995 Aug	7593712
Convulsive effects of tacrine.	1996 May 11	8622541
Tacrine, a reversible acetylcholinesterase inhibitor, induces myopathy.	2000 Apr 27	10817586
Therapeutic approaches to age-associated neurocognitive disorders.	2001 Sep	22033831
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.	2002 Dec	22034388
Effects of amphetamine on the plus-maze discriminative avoidance task in mice.	2002 Feb	11862369
Nicotine and sensory memory in Alzheimer's disease: an event-related potential study.	2002 Jul	15259398
Comparative effect of Prunus persica L. BATSCH-water extract and tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride) on concentration of extracellular acetylcholine in the rat hippocampus.	2003 Aug	12860300
The evaluation of cognitive function in the dementias: methodological and regulatory considerations.	2003 Mar	22033730
Reduction in distractibility with AF102B and THA in the macaque.	2003 Sep	14592682
Inhibition of murine cytochrome P4501A by tacrine: in vitro studies.	2004 Aug	15258105
Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.	2004 Aug	15246845
Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert.	2004 Feb 19	15036629
Simultaneous analysis of esterase and transferase activities in cytosol proteins from the bovine retina by using microscale non-denaturing two-dimensional electrophoresis.	2004 Jan 14	14726204
[Study of the cholinesterase active site using a fluorescent probe].	2004 Mar-Apr	15131977
Disclosure of a pro-apoptotic glyceraldehyde-3-phosphate dehydrogenase promoter: anti-dementia drugs depress its activation in apoptosis.	2004 May 14	15094325
Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats.	2005 Feb	15680188
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.	2006 Jul	16643965
Current therapeutic options for Alzheimer's disease.	2007 Dec	19415128
Allosteric modulation of muscarinic acetylcholine receptors.	2007 Sep	19305798
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008 Dec	18493746
NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.	2008 Dec 25	19053746
Cholinesterase inhibitors for delirium.	2008 Jan 23	18254077
1-Phenyl-6,7,8,9-hexa-hydro-1H,5H-cyclo-hepta-[1',2':2,3]pyrido[6,5-c]pyrazol-4-amine: a new tacrine analogue.	2008 May 10	21202575
The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats.	2008 Oct	18391858
Comparison studies of tacrine and bis7-tacrine on the suppression of scopolamine-induced behavioral changes and inhibition of acetylcholinesterase in mice.	2009	19365154
Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity.	2010 Jul 5	20512794
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

Oral Initially, 10 mg 4 times daily for at least 4 weeks. If well tolerated and increased serum ALT concentrations have not occurred, increase dosage to 20 mg 4 times daily; if tolerated, increase dosage in 40-mg daily increments (divided into 4 doses daily) at 4-week intervals up to a maximum of 160 mg daily (40 mg 4 times daily).

Route of Administration: Oral

In Vitro Use Guide

Tacrine (0.01-10 uM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 uM vs. 0.29 uM, respectively).

Substance Class	Chemical Created by `admin` on `Thu Jul 06 11:36:18 UTC 2023` Edited by `admin` on `Thu Jul 06 11:36:18 UTC 2023`
Record UNII	MQ603P8SBL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TACRINE HYDROCHLORIDE MONOHYDRATE

Common Name

English

9-ACRIDINAMINE, 1,2,3,4-TETRAHYDRO-, HYDROCHLORIDE, HYDRATE (1:1:1)

Systematic Name

English

9-ACRIDINAMINE, 1,2,3,4-TETRAHYDRO-, MONOHYDROCHLORIDE, MONOHYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

MQ603P8SBL

Created by admin on Thu Jul 06 11:36:18 UTC 2023 , Edited by admin on Thu Jul 06 11:36:18 UTC 2023

PRIMARY

EPA CompTox

DTXSID80221711

Created by admin on Thu Jul 06 11:36:18 UTC 2023 , Edited by admin on Thu Jul 06 11:36:18 UTC 2023

PRIMARY

PUBCHEM

6420002

Created by admin on Thu Jul 06 11:36:18 UTC 2023 , Edited by admin on Thu Jul 06 11:36:18 UTC 2023

PRIMARY

CAS

7149-50-0

Created by admin on Thu Jul 06 11:36:18 UTC 2023 , Edited by admin on Thu Jul 06 11:36:18 UTC 2023

PRIMARY

Related Record Type Details


					4VX7YNB537

TACRINE

PARENT -> SALT/SOLVATE


					4966RNG0BU

TACRINE HYDROCHLORIDE

ANHYDROUS->SOLVATE

Related Record Type Details


					4VX7YNB537

TACRINE

ACTIVE MOIETY

AE	Significance	Dose	Population
Abdominal pain	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Anorexia	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Diarrhea	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Dyspepsia	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Nausea	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Vomiting	21 patient Disc. AE	160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
Atrial fibrillation	1 patient Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Chest pain	1 patient Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Dyspnea	1 patient Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Transaminases increased	1 patient Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Nausea	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Pallor	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Sweating increased	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Transaminases increased	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Vasodilatation	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
Vomiting	1 patient Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00382Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00382
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

C_max

T_1/2